Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease

导致镰状细胞病血管功能障碍和疼痛的靶向机制

基本信息

  • 批准号:
    10424765
  • 负责人:
  • 金额:
    $ 8.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-04 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

Summary/Abstract Sickle cell disease (SCD), a recessive inherited disorder caused by a point mutation in the hemoglobin chain of red blood cells (RBCs). Microvascular dysfunction is central to the pathobiology of SCD, leading to life- threatening consequences. A major consequence is occlusion of activated microvasculature with sickle RBCs leading to unpredictable and frequent episodes of acute pain called vaso-occlusive crises (VOC), frequent hospitalization and poor quality of life. Many individuals with SCD suffer chronic pain that may start during infancy and continue to increase throughout life. Opioids are the mainstay for treatment but their side-effects and fear of addiction remain a major concern. Hence, a major unmet need is to prevent and/or treat pain more effectively. VOC is associated with increased hemolysis that releases free heme. Our preliminary data reveal that administration of free heme causes hyperalgesia (pain) in transgenic sickle mice expressing human sickle hemoglobin (Hb) and in control mice expressing normal human HbA. Our preliminary data shows that heme stimulates mast-cell extracellular traps (ETs) by releasing nuclear DNA and citrullinated histones. Mast- cell activation promotes hyperalgesia in sickle mice. We hypothesize that heme-induced mast-cell activation leads to release of citrullinated histones and noxious substances and contributes to inflammation, vascular dysfunction and axonal injury leading to vasoocclusion and hyperalgesia in SCD (Schema I). Mast cells may play a causal role in VOC and chronic pain in SCD. Targeting mast cells will ameliorate VOC and pain at its source. We will test our hypothesis using a translational approach with four specific aims to establish whether, heme contributes to chronic and/or acute hyperalgesia (Aim1), heme contributes to chronic/acute pain via mast-cell activation (Aim2), and heme-induced hyperalgesia is driven by novel mast cell–dependent mechanisms leading to axonal and vascular injury (Aim3), including, release of inflammatory cytokines, proteases, ETs with DNA and citrullinated histones from mast cells that cause axonal injury in the periphery and DRG neurons, and endothelial activation via endoplasmic reticulum stress. Aim4 will entail determining whether targeting the mechanisms of heme-induced mast- cell activation attenuates hyperalgesia and vaso-occlusion. We will use genetic and pharmacological approaches, namely [i] humanized transgenic HbSS-BERK sickle mice exclusively expressing human sickle Hb, [ii] HbAA-BERK control mice expressing normal human HbA, [iii] sickle mice deleted for, [a] mast cells or [b] TLR4 and their congenic controls; and mechanism-specific pharmacological inhibitors to prevent vaso- occlusion and pain. Mouse models and biologicals are available in our laboratories. By using multiple strategies in vivo and in vitro, involving mast cell–mediated hyperalgesia and their targeting with novel and/or FDA-approved drugs, we expect that our observations will lead to translationally relevant functional outcomes—reduction of VOC and acute as well as chronic pain in SCD.
摘要/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kalpna Gupta其他文献

Kalpna Gupta的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kalpna Gupta', 18)}}的其他基金

Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
  • 批准号:
    10207087
  • 财政年份:
    2021
  • 资助金额:
    $ 8.75万
  • 项目类别:
Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
  • 批准号:
    10377411
  • 财政年份:
    2021
  • 资助金额:
    $ 8.75万
  • 项目类别:
Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
  • 批准号:
    10614485
  • 财政年份:
    2021
  • 资助金额:
    $ 8.75万
  • 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
  • 批准号:
    10076288
  • 财政年份:
    2020
  • 资助金额:
    $ 8.75万
  • 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
  • 批准号:
    9906937
  • 财政年份:
    2019
  • 资助金额:
    $ 8.75万
  • 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
  • 批准号:
    10434654
  • 财政年份:
    2019
  • 资助金额:
    $ 8.75万
  • 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
  • 批准号:
    10095111
  • 财政年份:
    2019
  • 资助金额:
    $ 8.75万
  • 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
  • 批准号:
    8467856
  • 财政年份:
    2013
  • 资助金额:
    $ 8.75万
  • 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
  • 批准号:
    8722605
  • 财政年份:
    2013
  • 资助金额:
    $ 8.75万
  • 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
  • 批准号:
    8877627
  • 财政年份:
    2013
  • 资助金额:
    $ 8.75万
  • 项目类别:

相似海外基金

Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
  • 批准号:
    10603436
  • 财政年份:
    2023
  • 资助金额:
    $ 8.75万
  • 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10778757
  • 财政年份:
    2023
  • 资助金额:
    $ 8.75万
  • 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10783106
  • 财政年份:
    2023
  • 资助金额:
    $ 8.75万
  • 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
  • 批准号:
    10740796
  • 财政年份:
    2023
  • 资助金额:
    $ 8.75万
  • 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
  • 批准号:
    10599401
  • 财政年份:
    2022
  • 资助金额:
    $ 8.75万
  • 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
  • 批准号:
    575854-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.75万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
  • 批准号:
    467076
  • 财政年份:
    2021
  • 资助金额:
    $ 8.75万
  • 项目类别:
    Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    9979265
  • 财政年份:
    2020
  • 资助金额:
    $ 8.75万
  • 项目类别:
Endocannabinoid Metabolism in Acute Pain
急性疼痛中的内源性大麻素代谢
  • 批准号:
    10356880
  • 财政年份:
    2020
  • 资助金额:
    $ 8.75万
  • 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    10218273
  • 财政年份:
    2020
  • 资助金额:
    $ 8.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了